NeuroSense Therapeutics Ltd. (NRSN): who owns it and who trades it
As of Oct 30, 2026, NRSN insiders reported 1 purchase worth $200K in the last 12 months. The largest buyer was Alon Ben-Noon (CEO), with $200K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, NRSN insiders reported $200K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Alon Ben-Noon | CEO | Purchase | 250,000 | $0.80 | $200K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alon Ben-Noon | Chief Executive Officer | $200K | – | Jun 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NRSN short interest
27,182 NRSN shares are sold short. Over the last 12 reports the number of shares short went down 94%.
As of Oct 30, 2026, 27,182 NRSN shares were sold short, up 4.1% from the report before. At the average daily volume of 25,346 shares, buying them all back would take about 1.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 27,182 | – | +4% | 25,346 | 1.1 |
| Oct 15, 2026 | 26,105 | – | -3% | 21,750 | 1.2 |
| Sep 30, 2026 | 26,883 | – | -30% | 22,043 | 1.2 |
| Sep 15, 2026 | 38,236 | – | -92% | 40,192 | 1.0 |
| Aug 31, 2026 | 469,120 | – | -4% | 322,001 | 1.5 |
| Aug 14, 2026 | 489,130 | – | -11% | 212,026 | 2.3 |
| Jul 31, 2026 | 548,046 | – | +0% | 448,304 | 1.2 |
| Jul 15, 2026 | 547,543 | 1.68% | -6% | 78,661 | 7.0 |
| Jun 30, 2026 | 585,034 | 1.80% | +19% | 287,898 | 2.0 |
| Jun 15, 2026 | 491,665 | 1.51% | +33% | 149,482 | 3.3 |
| May 29, 2026 | 369,629 | 1.14% | -24% | 120,608 | 3.1 |
| May 15, 2026 | 487,264 | 1.50% | -15% | 135,258 | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
NeuroSense Therapeutics financials
Questions about NeuroSense Therapeutics Ltd. (NRSN) stock
Are NRSN insiders buying or selling?
In the last 12 months, NRSN insiders reported 1 open-market purchase worth $200K and no sales. The latest trade was on Jun 16, 2026. See every trade.
What is the short interest in NRSN?
As of Oct 30, 2026, 27,182 NRSN shares were sold short, up 4.1% from the report before. At the average daily volume of 25,346 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.